A look back at all the FDA news that happened in the month of November 2018, including several new approvals, priority reviews, a fast track designation, and an accelerated approval, across a variety of cancer types.
In November 2018, the FDA approved several agents for treatment of nonsmall cell lung cancer (NSCLC), multiple myeloma, peripheral T-cell lymphoma (PTCL), and acute myeloid leukemia (AML) among others. There were also 2 biosimilars approved: pegfilgrastim (Neulasta) and rituximab biosimilarCT-P10 (Truxima; rituximab-abbs).
There were also a number of priority reviews, a fast track designation, and an accelerated approval granted by the FDA during November 2018.
Take a look back on the FDA happenings for the month of November 2018:
Lorlatinib (Lorbrena) was granted an accelerated approval on November 2, 2018, as a treatment for patients withALK-positive metastatic NSCLC after progressing on 1 or more ALK tyrosine kinases inhibitors.
On November 5, 2018, the FDA approved egfilgrastim-cbqv (CHS-1701; Udencya), a pegfilgrastim biosimilar for treatment of patients with cancer receiving myelosuppressive chemotherapy. This was also approved by the European Commission in September 2018.
Based on data from the phase III ECHELON-2 trial, brentuximab vedotin (Adcetris) was submitted to the FDA for approval on November 6, 2018. This is indicated for use as a frontline treatment for patients with CD30-expressing peripheral T-cell lymphoma (PTCL).
On November 6, 2018, elotuzumab (Empliciti) received approval from the FDA for combination use with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) as treatment for patients with relapsed/refractory multiple myeloma who have receive at least 2 prior lines of therapy, including lenolidomide (Revlimid) and a proteasome inhibitor (PI).
The FDA granted a fast track designation to selinexor for treatment of patients with diffuse large B-cell lymphoma who were previously treated and ineligible to receive high-dose chemotherapy with stem cell rescue or chimeric antigen receptor (CAR) T-cell therapy. This decision, announced on November 7, 2018, was based on data from the phase IIb SADAL trial.
The FDA received a supplemental new drug application (sNDA) for avatrombopag (Doptelet) for treatment of patients with chronic immune thrombocytopenia (ITP) who have had an inadequate response to prior treatment. The sNDA was submitted on November 8, 2018, based on data from the phase III Amendment 02 trial.
On November 9, 2018, the FDA granted an accelerated approval to pembrolizumab (Keytruda) for treatment of patients with hepatocellular carcinoma (HCC) who have previously received sorafenib (Nexavar).
On November 12, 2018, the FDA granted priority review to olaparib tablets as a maintenance therapy in patients with newly-diagnosed,BRCA-positive advanced ovarian cancer who have already had a complete or partial response to a prior line of standard frontline platinum-based chemotherapy.
Atezolizumab (Tecentriq) received a priority review designation on November 13, 2018, for combination use with nab-paclitaxel in patients with unresectable locally advanced or metastatic PD-L1positive triple-negative breast cancer. The FDA is scheduled to make a decision by March 12, 2019.
The FDA granted approval of brentuximab vedotin (Adcetris) in combination with chemotherapy for treatment of patients with CD30-expressing PTCL in the frontline setting. This approval, on November 16, 2018, was based on data from the phase III ECHELON-2 trial.
On November 16, 2018, the FDA approved use of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia. This indication is an expansion to a previous approved for the eltrombopag combination.
An accelerated approval has been granted by the FDA for venetoclax (Venclexta) in combination use with azacytidine or decitabine or low-dose cytarabine as a frontline treatment for adult patients with newly-diagnosed AML who are aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. This decision was announced on November 21, 2018.
On November 21, 2018, the FDA granted approval of glasdegib (Daurismo) for combination use with low-dose cytarabine (LDAC) as treatment of patients with newly-diagnosed AML aged 75 year or older, or patients who are ineligible to receive intensive chemotherapy. The decision was based on data from a randomized trial of 111 patients.
An NDA was granted priority review for quizartinib as a treatment of adult patients with relapsed/refractoryFTL3-ITDpositive AML. The designation, announced on November 26, 2018, was based on data from the phase III QuANTUM-R study.
On November 26, 2018, the FDA granted an accelerated approval to larotrectinib (Vitrakvi) for treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment.
Rituximab biosimilar, CT-P10, was approved by the FDA on November 28, 2018, for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy. This is the first biosimilar approved for treatment of patients with NHL.